

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) January 10, 2025

---

**BECTON, DICKINSON AND COMPANY**

(Exact Name of Registrant as Specified in Its Charter)

---

**New Jersey**

(State or Other Jurisdiction of Incorporation)

---

**001-4802**

(Commission File Number)

---

**22-0760120**

(IRS Employer Identification No.)

---

**1 Becton Drive, Franklin Lakes, New Jersey**

(Address of Principal Executive Offices)

---

**07417-1880**

(Zip Code)

---

**(201) 847-6800**

(Registrant's Telephone Number, Including Area Code)

---

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

<u>Title of Each Class</u>	<u>Trading Symbol</u>	<u>Name of each exchange on which registered</u>
Common stock, par value \$1.00	BDX	New York Stock Exchange
1.900% Notes due December 15, 2026	BDX26	New York Stock Exchange
3.020% Notes due May 24, 2025	BDX25	New York Stock Exchange
1.208% Notes due June 4, 2026	BDX/26A	New York Stock Exchange
1.213% Notes due February 12, 2036	BDX/36	New York Stock Exchange
0.034% Notes due August 13, 2025	BDX25A	New York Stock Exchange
3.519% Notes due February 8, 2031	BDX31	New York Stock Exchange
3.828% Notes due June 7, 2032	BDX32A	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On January 9, 2025, the Board of Directors (the “Board”) of Becton, Dickinson and Company (the “Company”) appointed Pamela L. Spikner as Senior Vice President, Chief Accounting Officer and Controller, effective January 20, 2025. Christopher DeLorefice, Executive Vice President and Chief Financial Officer, will continue to serve as interim principal accounting officer until the Company files its Form 10-Q for the quarter ended December 31, 2024. Thereafter, Ms. Spikner will serve as the Company’s principal accounting officer.

Prior to joining the Company, Ms. Spikner, age 48, served as Chief Accounting Officer of R1 RCM since July 2021. Ms. Spikner also previously was Assistant Corporate Controller of Hill-Rom Holdings, Inc., a medical technology provider, from July 2019 to July 2021. Ms. Spikner held various accounting leadership roles at Exelon Corporation, a utility services holding company, from September 2007 to July 2019.

There are no arrangements or understandings between Ms. Spikner and any other person pursuant to which Ms. Spikner was appointed as principal accounting officer of the Company. Ms. Spikner does not have any family relationship with any director, or executive officer of the Company. The Company is not aware of any related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Ms. Spikner and the Company.

**ITEM 7.01. Regulation FD Disclosure.**

On January 10, 2025, BD issued a press release relating to the matters described above in Item 5.02. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The information in this Item 7.01 shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

---

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit [99.1](#) Press Release dated January 10, 2025.

Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: Stephanie M. Kelly /s/  
Stephanie  
M. Kelly Associate  
General Counsel, Securities and Governance and Assistant Secretary

Date: January 10, 2025



# NEWS RELEASE

## **BD Names Pamela Spikner as Chief Accounting Officer and Controller**

**Franklin Lakes, N.J. (January 10, 2025)** – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Pamela Spikner has been named senior vice president, chief accounting officer and controller, effective January 20.

In this role, Spikner will be responsible for all accounting policy and financial reporting for the company. She will report to Chris DeOrefice, executive vice president and chief financial officer.

“Pam has a proven track record of leadership in corporate finance and accounting, with a deep passion for building and leading high-performing teams,” said DeOrefice. “Her more than 25 years of expertise will play a pivotal role in the continued leadership of the finance organization at BD.”

Spikner joins BD from R1 RCM, Inc., which provides technology-enabled revenue cycle management solutions to health care providers, where she served as chief accounting officer since July 2021. In that role, she oversaw financial reporting and compliance, led strategic financial planning, implemented operational efficiency programs, among other responsibilities. She previously held various accounting leadership roles during her 12-year tenure at Exelon Corporation, a Fortune 200 company and the nation’s largest utility company, and served as assistant corporate controller from July 2019 through July 2021 at Hill-Rom Holdings, Inc., a medical device company. She began her career in the audit practice of PwC, where she worked with clients in the health care and insurance industries.

Pam holds a Bachelor of Science in Accounting from Indiana University of Pennsylvania. She is a certified public accountant (CPA) and a certified internal auditor (CIA).

###

### **About BD**

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

---

For more information on BD, please visit [bd.com](http://bd.com) or connect with us on LinkedIn at [www.linkedin.com/company/bd1/](http://www.linkedin.com/company/bd1/), X (formerly Twitter) [@BDandCo](https://twitter.com/BDandCo) or Instagram [@becton\\_dickinson](https://www.instagram.com/becton_dickinson).

**Contacts:**

Media: Investors:

Troy Kirkpatrick Adam Reiffe

VP, Public Relations Senior Director, Investor Relations

858.617.2361 201.847.6927

[troy.kirkpatrick@bd.com](mailto:troy.kirkpatrick@bd.com) [adam.reiffe@bd.com](mailto:adam.reiffe@bd.com)